http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24180430

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 7
issn 1687-8469
1687-8450
pageRange 785934-7
publicationName Journal of Oncology
startingPage 785934
bibliographicCitation Louvet C, André T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A. Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. Journal of Oncology. 2010;2010():1–7. doi: 10.1155/2010/785934.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40d2dcb0fc3d3012e514237fab5191cf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bafd0b25110b8a51f13db31f9775ab6c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_765cfd044b593663cfd29bd1a5352490
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8826f0a7231a46a84e7c19b476c846b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0dc074afdc47c82093d3e3502bd38bb7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_446d7ca564857c9052192962ccff61ae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_759202846a85930bd5e9352dda410b08
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2abf0b42103022a856f87559da78dbdd
date 2010
identifier https://doi.org/10.1155/2010/785934
https://pubmed.ncbi.nlm.nih.gov/PMC2852604
https://pubmed.ncbi.nlm.nih.gov/20396391
isPartOf https://portal.issn.org/resource/ISSN/1687-8469
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/35709
https://portal.issn.org/resource/ISSN/1687-8450
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136170999
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135659064
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128866026
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127502201
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129113875
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129555111
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127700914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520807
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129143706
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127946097
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127638306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128884697
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127838534
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128856633
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136058681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129281950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129909512

Total number of triples: 59.